Myelodysplastic Syndrome Stocks List

Recent Signals

Date Stock Signal Type
2021-04-14 ALXO Pocket Pivot Bullish Swing Setup
2021-04-14 ALXO Slingshot Bearish Bearish Swing Setup
2021-04-14 APRE Slingshot Bearish Bearish Swing Setup
2021-04-14 APRE Calm After Storm Range Contraction
2021-04-14 APRE 180 Bearish Setup Bearish Swing Setup
2021-04-14 ARGX 200 DMA Resistance Bearish
2021-04-14 CNST MACD Bullish Signal Line Cross Bullish
2021-04-14 CNST Slingshot Bearish Bearish Swing Setup
2021-04-14 KROS Volume Surge Other
2021-04-14 KROS 50 DMA Support Bullish
2021-04-14 LGND 20 DMA Resistance Bearish
2021-04-14 MRTX Stochastic Reached Oversold Weakness
2021-04-14 MRTX Slingshot Bearish Bearish Swing Setup
2021-04-14 MRUS Crossed Above 50 DMA Bullish
2021-04-14 MRUS Stochastic Sell Signal Bearish
2021-04-14 MRUS Expansion Pivot Buy Setup Bullish Swing Setup
2021-04-14 MRUS Pocket Pivot Bullish Swing Setup
2021-04-14 MRUS Spinning Top Other
2021-04-14 ONTX Stochastic Buy Signal Bullish
2021-04-14 SYRS Slingshot Bearish Bearish Swing Setup
2021-04-14 VINC Shooting Star Candlestick Bearish
2021-04-14 VINC Doji - Bearish? Reversal
2021-04-14 XLRN Lower Bollinger Band Walk Weakness

Recent News for Myelodysplastic Syndrome Stocks

Date Stock Title
Apr 15 SYRS Cathie Wood Trims Tesla Stake And Loads Up Heavily On Coinbase
Apr 14 SYRS Cathie Wood Furthers Bet On Virgin Galactic, Also Adds DraftKings, Atlassian, Peloton
Apr 13 SYRS Cathie Wood Buys Yet Another Workhorse Dip, Also Adds DraftKings, Peloton, Square
Apr 12 MRTX Mirati Therapeutics Inc (MRTX) Presents at AACR Virtual Meeting 2021 - Slideshow
Apr 12 MRTX BeiGene's tislelizumab combo study shows antitumor activity in solid tumors
Apr 10 MRTX Mirati Therapeutics Presents Preclinical Data on Novel Approach to PRMT5 Inhibition that Selectively Targets the PRMT5/MTA Complex in MTAP-Deleted Cancer Models
Apr 10 MRTX The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight
Apr 10 VINC Vincerx Pharma Presents Preclinical Data on VIP236, its Lead Small Molecule Drug Conjugate, at the American Association for Cancer Research Annual Meeting 2021
Apr 10 VINCU Vincerx Pharma Presents Preclinical Data on VIP236, its Lead Small Molecule Drug Conjugate, at the American Association for Cancer Research Annual Meeting 2021
Apr 9 MRTX Seeking Alpha Catalyst Watch
Apr 9 SYRS Cathie Wood Seems To Be Bullish On Elon Musk-Led SpaceX's 3D Printer Supplier Velo3D — And More
Apr 8 APRE Aprea Therapeutics shares rise after leukemia treatment gets FDA orphan drug status
Apr 8 APRE Aprea Therapeutics Receives FDA Orphan Drug Designation for Eprenetapopt for the Treatment of Acute Myeloid Leukemia (AML)
Apr 8 CNST Is CNST Stock A Buy or Sell?
Apr 8 KROS Investors Who Bought Keros Therapeutics (NASDAQ:KROS) Shares A Year Ago Are Now Up 204%
Related Industries: Biotechnology Shell Companies

Myelodysplastic syndromes (MDS) are a group of cancers in which immature blood cells in the bone marrow do not mature and therefore do not become healthy blood cells. Early on, there are typically no symptoms. Later symptoms may include feeling tired, shortness of breath, easy bleeding, or frequent infections. Some types may develop into acute myeloid leukemia.Risk factors include previous chemotherapy or radiation therapy, exposure to certain chemicals such as tobacco smoke, pesticides, and benzene, and exposure to heavy metals such as mercury or lead. Problems with blood cell formation result in some combination of low red blood cells, low platelets, and low white blood cells. Some types have an increase in immature blood cells, called blasts, in the bone marrow or blood. The types of MDS are based on specific changes in the blood cells and bone marrow.Treatments may include supportive care, drug therapy, and stem cell transplantation. Supportive care may include blood transfusions, medications to increase the making of red blood cells, and antibiotics. Drug therapy may include the medication lenalidomide, antithymocyte globulin, and azacitidine. Certain people can be cured with chemotherapy followed by a stem-cell transplant from a donor.About seven per 100,000 people are affected with about four per 100,000 people newly acquiring the condition each year. The typical age of onset is 70 years. The outlook depends on the type of cells affected, the number of blasts in the bone marrow or blood, and the changes present in the chromosomes of the affected cells. The typical survival time following diagnosis is 2.5 years. The conditions were first recognized in the early 1900s. The current name came into use in 1976.

More about Myelodysplastic Syndrome
Browse All Tags